% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vandenBent:1047083,
      author       = {van den Bent, Martin J and Vogelbaum, Michael A and
                      Cloughesy, Tim and Galldiks, Norbert and Albert, Nathalie L
                      and Tonn, Joerg-Christian and Avila, Edward and Fangusaro,
                      Jason and Mirsky, David and Sahgal, Arjun and Soffietti,
                      Ricardo and Karschnia, Philipp and Mehta, Minesh and Kim,
                      Michelle M and Boele, Florien and Huse, Jason T and Nayak,
                      Lakshmi and Lim-Fat, Mary Jane and le Rhun, Emilie and
                      Desjardins, Annick and Lee, Eudocia Q and Chukwueke, Ugonma
                      and Koekkoek, Johan A F and Mendoza, Tito and Loughan,
                      Ashlee R and Budhu, Joshua A and Bakas, Spyridon and Huang,
                      Raymond Y and Villanueva-Meyer, Javier E and Leone, Jose
                      Pablo and Okada, Hideho and Reardon, David A and Bi, Wenya L
                      and Wen, Patrick Y and Chang, Susan M},
      title        = {{R}esponse {A}ssessment in {N}euro-{O}ncology ({RANO})
                      2009–2025: {B}road scope and implementation—{A} progress
                      report},
      journal      = {Neuro-Oncology},
      volume       = {27},
      number       = {9},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2025-04109},
      pages        = {2209–2224},
      year         = {2025},
      abstract     = {AbstractSince its first activities in 2008 and 2009, the
                      Response Assessment in NeuroOncology (RANO) group has given
                      guidance on response assessment, trial design, and trial
                      procedures to improve and standardize the way clinical
                      trials in neurooncological studies are performed. To achieve
                      its objectives, a variety of working groups have been
                      initiated that cover many aspects of clinical trial design
                      and outcome assessment in patients with tumors affecting the
                      Central Nervous System. The RANO working groups are built on
                      expertise without a formal structure, which makes rapid
                      responses to new developments possible. RANO is aiming at
                      evidence-based guidelines and recommendations, but in the
                      absence of evidence will provide consensus-based guidance
                      achieved by inviting recognized international experts. In
                      its 15 years of existence, more than 60 RANO papers have
                      been published mostly in high-ranking journals, and its
                      recommendations have been accepted by regulators and
                      industry as guiding principles. RANO organizes two meetings
                      per year, one in conjunction with the annual American
                      Society for Clinical Oncology (ASCO) meeting, and one during
                      the annual Society for Neuro-Oncology meeting. These
                      meetings are open, as are the working groups of RANO. New
                      initiatives are welcomed.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1093/neuonc/noaf118},
      url          = {https://juser.fz-juelich.de/record/1047083},
}